TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00764465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400 mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID, 100 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID, 100 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID, 100 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100 mg BID, 100 mg QD
Study: NCT04146259

Intervention type: DRUG
Intervention: calcium carbonate and alphacalcidol
Description: treatment for hypocalcemia
Study: NCT02452892

Intervention type: DEVICE
Group type: OTHER
Intervention: LFMS
Description: Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LFMS
Description: Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LFMS
Description: Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LFMS
Description: Low field magnetic stimulation (1 kilohertz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
Study: NCT02534428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wool clothing
Description: superfine merino wool ensembles for baby wear

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wool clothing
Description: superfine merino wool ensembles for baby wear
Study: NCT03085160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning to Breathe
Description: Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
Study: NCT02996266

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management
Description: Prophylactic normothermia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: No intervention to control temperature unless fever occurs
Study: NCT02688452

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Unmodified Placebo Water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Electrokinetically modified water (EMW)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Electrokinetically modified water (EMW)
Study: NCT02003092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-5902
Description: escalating doses (mg)
Study: NCT04555694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Used to increase tear production in patients who have dry eye caused by inflammation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Used to increase tear production in patients who have dry eye caused by inflammation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol Etabonate
Description: Used to treat inflammation of the eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Ophthalmic 0.4 Mg Ophthalmic Insert
Description: Used to treat inflammation of the eye
Study: NCT03968276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use of digital tablet
Description: At the end of hospitalization, the patient has an educational tablet at his disposal for 1 month at home. Throughout its use, the patient may contact the investigating physician via a telephone number available within the application if he/she encounters a problem related to the study. At the end of this month, the patient must complete two questionnaires through the application to assess his or her knowledge of his or her condition and treatment, as well as his or her satisfaction with the use of the tablet.~In this research, 1 month after inclusion, the patient will have an additional follow-up visit corresponding to a dedicated consultation in the vascular medicine department. It will allow the patient to review the use of the tablet and his or her satisfaction with the use of such a tool.
Study: NCT01655199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination ipratropium/salbutamol or placebo (nebulization)
Description: For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
Study: NCT03161509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: single dose of 1 gr paracetamol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)
Description: Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
Study: NCT03627299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300mg glecaprevir/pibrentasivir 120mg
Description: 300mg glecaprevir/pibrentasivir 120mg 4 weeks post-transplant
Study: NCT02688452

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Unmodified Placebo Water
Study: NCT01128673

Intervention type: DEVICE
Intervention: mRI

Intervention type: DEVICE
Intervention: mRI
Study: NCT03323502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP Specialist Program
Description: New structured role with responsibility for ACP
Study: NCT01718223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo interstitial photodynamic therapy using temoporfin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temoporfin
Description: Undergo interstitial photodynamic therapy using temoporfin
Study: NCT04376788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: exchange blood transfusion from normal donor
Description: IV method

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: exchange blood transfusion from normal donor
Description: IV method

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plasma from convalescent patients with COVID-19
Description: IV method

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plasma from convalescent patients with COVID-19
Description: IV method

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue 5 MG/ML
Description: IV method

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue 5 MG/ML
Description: IV method
Study: NCT03029585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 100 mg/m2
Description: Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 200 mg/m2
Description: Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 300 mg/m2
Description: Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoPac® 400 mg/m2
Description: Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Intravenous Chemotherapy
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Intravenous Chemotherapy
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Intravenous Chemotherapy
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Intravenous Chemotherapy
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Intravenous Chemotherapy
Description: Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
Study: NCT02540915

Intervention type: OTHER
Intervention: Standard of Care - Registry
Description: Standard of Care - Registry
Study: NCT02301507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cell phone SMS text messaging
Description: This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
Study: NCT04543669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel®
Description: Vaccine for TdaP-Tetanus, diphtheria, acellular pertussis
Study: NCT01000935

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
Study: NCT04690309

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with human insulin preparations or treatment with insulin analogues
Description: The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with human insulin preparations or treatment with insulin analogues
Description: The doses of human insulin preparations and insulin analogues will be matched individually to achieve target values of blood glucose - fasting \< 100 mg/dl (5.5 mmol/L) and postprandial \< 140 mg/dl (7.8mmol/L)
Study: NCT02240810

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention (Promus PREMIER)
Description: Interventional coronary artery stenting with Promus PREMIER study stent.
Study: NCT00470756

Intervention type: OTHER
Intervention: mechanical triggering of peroneal activity
Description: mechanical triggering of peroneal activity
Study: NCT03100851

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota
Description: a bottle of 100 mililiter probiotic dairy beverage containing 10\^8 CFU Lactobacillus casei strain Shirota every day after lunch.
Study: NCT01185340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSRI
Description: Participants should have been on their SSRI for at least 6 weeks prior and were to continue on their stable dose throughout the study
Study: NCT02144285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3113593
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3113593
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3113593
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02741921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight DL
Description: intubation using VivaSight DL tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight DL
Description: intubation using VivaSight DL tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional double-lumen tube
Description: intubation using conventional double-lumen tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional double-lumen tube
Description: intubation using conventional double-lumen tube
Study: NCT02802176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOcell device
Description: intra-vaginal culture of embryos using INVOcell device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional IVF
Description: traditional culture of embryos in-vitro
Study: NCT01752816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Study: NCT04246905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulforaphane
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placedo
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: selective 5 - HT reuptake inhibitors (SSRI)
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selective 5 - HT reuptake inhibitors (SSRI)
Description: To examine the add-on effect of sulforaphane in depression patients with selective 5 - HT reuptake inhibitors (SSRI) treatment
Study: NCT04135183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: changes of Pneumonia Severity Score
Description: assessing effectiveness of CAP treatment by using continuous pneumonia severity score

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: changes of Pneumonia Severity Score
Description: assessing effectiveness of CAP treatment by using continuous pneumonia severity score

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: changes of Pneumonia Severity Score
Description: assessing effectiveness of CAP treatment by using continuous pneumonia severity score
Study: NCT02707328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Study: NCT03843983

Intervention type: DEVICE
Group type: OTHER
Intervention: Lipiflow® application
Description: Lipiflow® will be applicated in both lids of each eye during 12 minutes once. Firstly, a drop of anesthetic will be instilled in each eye. Then, while the participant stays with his eyes closed, a one-used applicator will be placed covering the subject's lid. The instrument applies heat and pressure in the lid during 12 minutes. Time frame: between 2 and 7 days after visit 1.~Then, there will be 3 follow-up visits in 3, 6 and 12 months after treatment.
Study: NCT00806728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-507
Description: 0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
Study: NCT01848483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIDS EPC Package plus MI
Description: 1. Motivational Interviewing: In MI session #1, the nurse will set the agenda \& ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 \& 4, the nurse will also introduce advance care planning.~2. EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic \& conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation \& coordination of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care (SOC)
Description: The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts Antiretroviral therapy (ART), an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
Study: NCT00947895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: IV 1000 mg daily for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTH
Description: IM ACTH 80 mg/day for 5 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV placebo
Description: IV placebo (saline) daily for 3 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IM placebo
Description: IM placebo (saline) daily for 5 days.
Study: NCT03327025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education counseling
Description: Health education counseling